Cargando…

Analysis of PD-1 related immune transcriptional profile in different cancer types

BACKGROUND: Programmed cell death 1 (PD-1) functions as an immune checkpoint in the process of anti-tumor immune response. The PD-1 blockade is now becoming a fundamental part in cancer immunotherapy. So it’s essential to elicit the PD-1 related immune process in different types of cancer. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Jun, Song, Qian, Yang, Zuyi, Sun, Xiaoyan, Xue, Meijuan, Chen, Wenjie, Yang, Jingcheng, Wang, Sihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307327/
https://www.ncbi.nlm.nih.gov/pubmed/30607140
http://dx.doi.org/10.1186/s12935-018-0712-y
_version_ 1783382983770636288
author Shang, Jun
Song, Qian
Yang, Zuyi
Sun, Xiaoyan
Xue, Meijuan
Chen, Wenjie
Yang, Jingcheng
Wang, Sihua
author_facet Shang, Jun
Song, Qian
Yang, Zuyi
Sun, Xiaoyan
Xue, Meijuan
Chen, Wenjie
Yang, Jingcheng
Wang, Sihua
author_sort Shang, Jun
collection PubMed
description BACKGROUND: Programmed cell death 1 (PD-1) functions as an immune checkpoint in the process of anti-tumor immune response. The PD-1 blockade is now becoming a fundamental part in cancer immunotherapy. So it’s essential to elicit the PD-1 related immune process in different types of cancer. METHODS: The Cancer Genome Atlas was used to collect the RNA-seq data of 33 cancer types. The microenvironment cell populations-counter was used to analyze the immune cell infiltrates. KEGG and GO analysis were performed to investigate PD-1 associated biological process. Kaplan–Meier survival curves and Cox’s proportional hazards model were performed for prognostic value analysis. RESULTS: We demonstrated that PD-1 expression varied in different cancer types. The uveal melanoma had a low PD-1 expression and poor infiltrated with immune cells. But it showed the strong correlation of PD-1 with the most types of immune cells. The PD-1 demonstrated a robust relationship with other immunomodulators and showed its involvement in critical functions correlated with anti-tumor immune pathways. Survival analysis indicated the PD-1 expression suggested different prognosis in different cancer types. CONCLUSIONS: Our investigations promote a better understanding of the PD-1 blockade and provide PD-1 related personized combined immunotherapy for different types of cancer patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12935-018-0712-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6307327
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63073272019-01-03 Analysis of PD-1 related immune transcriptional profile in different cancer types Shang, Jun Song, Qian Yang, Zuyi Sun, Xiaoyan Xue, Meijuan Chen, Wenjie Yang, Jingcheng Wang, Sihua Cancer Cell Int Primary Research BACKGROUND: Programmed cell death 1 (PD-1) functions as an immune checkpoint in the process of anti-tumor immune response. The PD-1 blockade is now becoming a fundamental part in cancer immunotherapy. So it’s essential to elicit the PD-1 related immune process in different types of cancer. METHODS: The Cancer Genome Atlas was used to collect the RNA-seq data of 33 cancer types. The microenvironment cell populations-counter was used to analyze the immune cell infiltrates. KEGG and GO analysis were performed to investigate PD-1 associated biological process. Kaplan–Meier survival curves and Cox’s proportional hazards model were performed for prognostic value analysis. RESULTS: We demonstrated that PD-1 expression varied in different cancer types. The uveal melanoma had a low PD-1 expression and poor infiltrated with immune cells. But it showed the strong correlation of PD-1 with the most types of immune cells. The PD-1 demonstrated a robust relationship with other immunomodulators and showed its involvement in critical functions correlated with anti-tumor immune pathways. Survival analysis indicated the PD-1 expression suggested different prognosis in different cancer types. CONCLUSIONS: Our investigations promote a better understanding of the PD-1 blockade and provide PD-1 related personized combined immunotherapy for different types of cancer patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12935-018-0712-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-27 /pmc/articles/PMC6307327/ /pubmed/30607140 http://dx.doi.org/10.1186/s12935-018-0712-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Shang, Jun
Song, Qian
Yang, Zuyi
Sun, Xiaoyan
Xue, Meijuan
Chen, Wenjie
Yang, Jingcheng
Wang, Sihua
Analysis of PD-1 related immune transcriptional profile in different cancer types
title Analysis of PD-1 related immune transcriptional profile in different cancer types
title_full Analysis of PD-1 related immune transcriptional profile in different cancer types
title_fullStr Analysis of PD-1 related immune transcriptional profile in different cancer types
title_full_unstemmed Analysis of PD-1 related immune transcriptional profile in different cancer types
title_short Analysis of PD-1 related immune transcriptional profile in different cancer types
title_sort analysis of pd-1 related immune transcriptional profile in different cancer types
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307327/
https://www.ncbi.nlm.nih.gov/pubmed/30607140
http://dx.doi.org/10.1186/s12935-018-0712-y
work_keys_str_mv AT shangjun analysisofpd1relatedimmunetranscriptionalprofileindifferentcancertypes
AT songqian analysisofpd1relatedimmunetranscriptionalprofileindifferentcancertypes
AT yangzuyi analysisofpd1relatedimmunetranscriptionalprofileindifferentcancertypes
AT sunxiaoyan analysisofpd1relatedimmunetranscriptionalprofileindifferentcancertypes
AT xuemeijuan analysisofpd1relatedimmunetranscriptionalprofileindifferentcancertypes
AT chenwenjie analysisofpd1relatedimmunetranscriptionalprofileindifferentcancertypes
AT yangjingcheng analysisofpd1relatedimmunetranscriptionalprofileindifferentcancertypes
AT wangsihua analysisofpd1relatedimmunetranscriptionalprofileindifferentcancertypes